Anxiety disorders and obsessive compulsive disorder

Neuropsychobiology

Volumn 37, Issue 2, 1998, Pages 69-71

  Liebowitz, Michael R ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Long term treatment; Obsessive compulsive; Panic; Social phobia

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; OBSESSION; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER;

EID: 0031890154     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026480     Document Type: Conference Paper

References (17)

1. Klein DF: Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
2. Westenberg HG, Den Boer JA: New findings in the treatment of panic disorder. Pharmacopsychiatry. 1993;26(suppl 1):30-33.
3. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59.
4. Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine theory in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:313.
5. Mavissakalian M, Perel JM: Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149:1053-1057.
6. Noyes R, Garvey MJ, Cook BL, Samuelson L: Problems with tricyclic antidepressants use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. J Clin Psychiatry 1989;50:5:163-169.
7. Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, Solyom C: Long term follow-up after a drug trial for panic disorder. Br J Psychiatry 1995;167:487-494.
8. Curtis G, Massana J, Udina C, Luis J, Ayuso JL, Cassano GB, Perugi G: Maintenance drug therapy of panic disorder. J Psychiat Res 1993; 27(suppl 1):127-142.
9. Coplan JD, Papp L, Martinez J, Pine D, Rosenblum L, Cooper T, Liebowitz M, German J: Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 1995;152:619-622.
10. Brown T, Barlow D: Long-term outcome in cognitive-behavioral treatment of panic disorder. Clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995;5:754-765.
11. Wiborg IM, Dahl AA: Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 1996;53:689-694.
12. Schneier F, Juster H, Heimberg R, Liebowitz M: Diagnosis and treatment of social phobia. J Pract Psychiatr Behav Health 1996;2:94-104.
13. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study. Arch Gen Psychiatry 1991;48:938-945.
14. Greist JH, Jefferson JW, Kobak KA, Katznelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder: A meta-analysis. Arch Gen Psychiatry 1995;52:53-60.
15. Zohar J, Judge R: OCD Paroxetine Study Investigators. Paroxetinc versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474.
16. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenike MA: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. J Clin Psychopharmacol 1996;16(2):121-129.
17. Pato MT, Zoka-Kadouch R, Zohar J, Murphy DL: Return of symptoms after discontinuation of clomipramine and patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145:1521-1525.